Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | S100B | P04271 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865779 | 0.91 | LMNA (0.58) | LMNAHTTSMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL408310 | 0.84 | CYP2C9 (0.67) | LMNAHTTSMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL2522600 | 0.84 | LMNA (0.53) | SRD5A2LMNAHTTSMN1; SMN2CYP2C9 | |
| SCHEMBL2905374 | 0.83 | NPC1 (0.57) | NR1H4EPHX2SMN1; SMN2GAA | |
| SCHEMBL21611105 | 0.83 | SRD5A2 (0.50) | SRD5A2TP53TSHRNR1H4EPHX2 | |
| SCHEMBL22458909 | 0.83 | KDM4E (0.44) | TP53LMNASMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL13701770 | 0.83 | HDAC2 (0.59) | TSHRLMNAHTTNR1H4EPHX2 | |
| Hydrochloric Acid SCHEMBL22076570 | 0.83 | CYP2C9 (0.65) | LMNAHTTSMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL2264435 | 0.83 | ALDH1A1 (0.61) | TP53LMNAHTTSMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL6851253 | 0.83 | CYP2C9 (0.65) | LMNAHTTSMN1; SMN2CYP2C9EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-6001880-A | DISUBSTITUTED N-(2-DIALKYLAMINOETHYL)BENZAMIDE DERIVATIVES OF GIVEN FORMULA; ANTIBACTERIAL ACTIVITY AGAINST HELICOBACTER PYROLI, ADMINISTERING FOR THE PREVENTION OR CURE OF PEPTIC ULCERS | SHISEIDO CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0875501-A2 | Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | SRD5A2 943/4885TP53 878/4885TSHR 4423/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | SRD5A2 464/4885TP53 565/4885TSHR 4178/4885 |
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | SRD5A2 590/4885TP53 3308/4885TSHR 2457/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | SRD5A2 562/4885TP53 4782/4885TSHR 911/4885 |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | SRD5A2 590/4885TP53 3308/4885TSHR 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.